Suite 720, 999 West Broadway
Vancouver BC V5Z 1K5 Canada
Phone: (778) 331-0962
Member Sector: Biopharmaceuticals
ESSA is developing drugs which selectively block the N-terminus of the androgen receptor, potentially by-passing all the known mechanisms of Castrate-Resistant Prostate Cancer, providing recurrent prostate cancer patients the potential for significant increases in progression-free survival.